Russell Schundler Sells 7,836 Shares of Liquidia Technologies, Inc. (NASDAQ:LQDA) Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 7,836 shares of Liquidia Technologies stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total transaction of $111,898.08. Following the completion of the transaction, the general counsel directly owned 577,977 shares of the company's stock, valued at $8,253,511.56. This trade represents a 1.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Liquidia Technologies Stock Down 1.3%

LQDA traded down $0.19 on Friday, reaching $14.41. 929,859 shares of the company traded hands, compared to its average volume of 1,301,902. The stock's 50 day moving average price is $14.88 and its 200-day moving average price is $14.48. Liquidia Technologies, Inc. has a 52-week low of $8.26 and a 52-week high of $19.41. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -9.14 and a beta of -0.01. The company has a debt-to-equity ratio of 2.08, a current ratio of 2.93 and a quick ratio of 2.91.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. On average, sell-side analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia Technologies

A number of hedge funds have recently made changes to their positions in the business. Ballentine Partners LLC raised its stake in shares of Liquidia Technologies by 10.2% in the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company's stock valued at $151,000 after buying an additional 1,119 shares in the last quarter. Whitcomb & Hess Inc. raised its stake in shares of Liquidia Technologies by 30.6% in the 2nd quarter. Whitcomb & Hess Inc. now owns 27,827 shares of the company's stock valued at $347,000 after buying an additional 6,527 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Liquidia Technologies by 6.0% in the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company's stock valued at $1,261,000 after buying an additional 4,811 shares in the last quarter. Bluefin Capital Management LLC acquired a new position in shares of Liquidia Technologies in the 1st quarter valued at $250,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Liquidia Technologies by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company's stock valued at $1,796,000 after buying an additional 16,022 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Analysts Set New Price Targets

LQDA has been the subject of a number of analyst reports. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer set a $13.00 target price on shares of Liquidia Technologies and gave the company an "underperform" rating in a research note on Monday, May 19th. Wells Fargo & Company boosted their target price on shares of Liquidia Technologies from $23.00 to $25.00 and gave the company an "overweight" rating in a research note on Thursday, June 12th. BTIG Research reissued a "buy" rating on shares of Liquidia Technologies in a research note on Tuesday, May 27th. Finally, Raymond James Financial boosted their target price on shares of Liquidia Technologies from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.89.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).